24 Students Qualify for RTX MATHCOUNTS® National Competition
ALEXANDRIA, VA, UNITED STATES, March 7, 2025 / EINPresswire.com / -- The MATHCOUNTS® Foundation hosted its first round of state competitions this weekend. Alabama, Connecticut, Kansas, Massachusetts, Rhode Island and South Carolina have announced their top students who will advance to the 2025 RTX MATHCOUNTS National Competition in May:
• From Alabama: Henry Gladden of Mobile, Austin Lu of Birmingham, Jessie Shi of Vestavia and Minlu Wang-He of Auburn.
• From Connecticut: Hayden Hughes of Newtown, Ethan Shi of Riverside, Alex Svoronos of Greenwich and Elaine Zhou of Hamden.
• From Kansas: Haidan Anderson of Overland Park, Ruby Jiang of Lawrence, Christopher Spencer of Manhattan and Jayden Xue of Overland Park.
• From Massachusetts: Eric Huang of Acton, Shlok Mukund of Lexington, Brandon Ni of Lexington and Soham Samanta of Medford.
• From Rhode Island: Kahlan Anderson of the Wheeler School, Julian Bernhoft of Providence, Colin Hegstrom of Providence and Theodora Watson of Barrington.
• From South Carolina: Yukai Hu of Elgin, Justin Peng of Clemson, Geonhoo Shim of Columbia and Aaron Wang of Mount Pleasant.
These state competitions are the third level of competition in the MATHCOUNTS Competition Series for students in sixth through eighth grade. The Mathletes® attending were top performers at the school level who also scored highly at one of 500 local chapter competitions in February.
The competitions involved:
• a 40-minute, 30-problem Sprint Round without calculators to test accuracy
• a 30-minute, eight-problem Target Round with calculators to test mathematical reasoning
• a 20-minute, 10-problem Team round with calculators to test teamwork skills
• an optional Countdown Round—a fast-paced oral competition
All MATHCOUNTS state competitions are organized by volunteer coordinators who receive support from the MATHCOUNTS national staff. Fifty more U.S. states and territories will announce 200 more national competitors this month after hosting their state competitions.
The RTX MATHCOUNTS National Competition will take place in Washington, D.C. from May 10-12. Over 200 total Mathletes will vie for the title of National Champion, an honor that comes with a $20,000 college scholarship.
'We can't wait to welcome these talented problem solvers to Washington in May,' said Kristen Chandler, executive director of the MATHCOUNTS Foundation. 'Reaching the national level of competition is an impressive feat, one that we're excited to celebrate with the support of RTX.'
About MATHCOUNTS:
MATHCOUNTS is a non-profit organization that strives to engage middle school students of all ability and interest levels in fun, challenging math programs to expand their academic and professional opportunities. Middle school students exist at a critical juncture in which their love for mathematics must be nurtured, or their fear of mathematics must be overcome. MATHCOUNTS provides free, high-quality resources to educators and enriching, extracurricular opportunities to students to lay a foundation for future success. Learn more about scholarships, programs and math resources at www.mathcounts.org.
Molly Gormley
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28-07-2025
- Yahoo
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma. As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration. "This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond." NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates. "The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS. "This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS. The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond. "The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options." About Elpis Biopharmaceuticals Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit Contact Tiberend Strategic Advisors, Inc. Jonathan Nugent (investors) +1-205-566-3026 jnugent@ Eric Reiss (media) ereiss@ View original content: SOURCE Elpis Biopharmaceuticals Sign in to access your portfolio
Yahoo
12-07-2025
- Yahoo
The July full moon will create an optical illusion. Peak time to see the 'Buck moon' in RI
July's full moon, known as the Buck Moon, is rising this week – with a trick. On July 10, July's full moon will be at its peak at 4:37 p.m. ET, according to the Old Farmer's Almanac. It will be below the horizon when it reaches its peak, but you can face southeast to watch the moon rise following sunset. The full moon will be visible from July 9 to July 10, according to NASA. The trick will be when it rises. The Earth is currently just about at its farthest point from the sun in its orbit, according to Live Science, which means the moon is also at its farthest point. This creates an interesting moon rise, where is will appear low in the sky, giving it an unnaturally large appearance known as the moon illusion. "Photographs prove that the moon is the same width near the horizon as when it's high in the sky, but that's not what we perceive with our eyes," NASA says. "Thus, it's an illusion rooted in the way our brains process visual information. Even though we've been observing it for thousands of years, there's still not a satisfying scientific explanation for exactly why we see it." The weather is looking less than ideal for watching a moonrise. AccuWeather is forecasting clouds and rain on July 9 and clouds and thunderstorms on July 10 in Providence. The Buck Moon, a Native American term, is called as such because "the antlers of male deer (bucks) are in full-growth mode at this time," according to the Farmer's Almanac. "Bucks shed and regrow their antlers each year, producing a larger and more impressive set as the years go by." According to the Farmer's Almanac, they include: Feather Moulting Moon (Cree) Salmon Moon, (Tlingit) Berry Moon (Anishinaabe) When the Chokecherries are Ripe (Dakota) Month of the Ripe Corn Moon (Cherokee) Raspberry Moon (Algonquin, Ojibwe) Thunder Moon (Western Abenaki) Halfway Summer Moon (Anishinaabe) A full moon can be seen clearly with the naked eye. But in a past interview with USA Today Network, Tim Brothers, Massachusetts Institute of Technology technical Instructor and observatory manager, said with any case of stargazing, it's much better if you're using a good telescope or a pair of binoculars. According to Time and Date, they include: Sturgeon Moon: Aug. 9, 2025 Corn Moon: Sept. 7, 2025 Harvest Moon: Oct. 6, 2025 Beaver Moon: Nov. 5, 2025 Cold Moon: Dec. 4, 2025 The USA Today Network contributed to this report. This article originally appeared on The Providence Journal: July full moon will create 'moon illusion.' When to see it in RI
Associated Press
30-06-2025
- Associated Press
Vitalgen's Gene Therapy Drug VGN-R09b for Primary Parkinson's Disease Receives FDA Fast Track Designation
SHANGHAI, CHINA, June 30, 2025 / / -- Shanghai Vitalgen BioPharma Co., Ltd. ('Vitalgen') announced that its gene therapy drug, VGN-R09b, for the treatment of Primary Parkinson's Disease (PD), has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). VGN-R09b received IND approvals in China and the US in 2024, as a first-in-class recombinant adeno-associated virus (rAAV) gene therapy that targets two key pathways for the treatment of Parkinson's Disease (PD). The Phase I/II clinical trials have been ongoing in China since September, 2024, with all six patients dosed in the Phase I dose-escalation study. Safety data shows that the product is well-tolerated with no findings of VGN-R09b-related adverse events. Preliminary efficacy readouts show that VGN-R09b has a rapid onset of action, with significant gait improvements within two weeks post-treatment. The MDS-UPDRS Part III OFF scores decreased significantly after one month, with an average of 25-point improvements (approximately 50% improvements from the baseline) at six months. Overall, the Hoehn-Yahr (H-Y) scores progressively decreased, along with a reduction in oral medication dosages. The FTD indicates FDA's recognition of the clinical potential of VGN-R09b, marking an important milestone for Vitalgen's expansion into the chronic disease area, and it also represents a global breakthrough for a Chinese gene therapy company in the neurodegenerative field. Together with its FDA IND approval in July 2024, this FTD further validates VGN-R09b's global development potential and will provide expedited support for its future US clinical trials and regulatory filings. About Fast Track Designation (FTD) FTD is an FDA program designed to accelerate the development and approval of drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs. According to the performance report from the FDA's Center for Biologics Evaluation and Research (CBER), over 800 products have applied for FTD, with a success rate of approximately 68%. After receiving FTD, applicants are given the opportunity for frequent discussions with the FDA regarding their drug development plans, thereby increasing development efficiency. If the product meets certain criteria, it can qualify for accelerated approval, priority review, and rolling reviews, which can further accelerate development and market approval processes. About Parkinson's Disease (PD) Parkinson's Disease (PD) is the second most common neurodegenerative disease, with fast-growing incidences. It is projected that the global PD patient numbers will increase to more than 25 million by 2050. Current PD treatments are primarily small-molecule drugs for symptom relief. As the disease progresses, patients gradually lose response to oral medication, and significant motor complications persist despite fine-tuning the treatment regimens. There is currently no available treatment to delay disease progression or improve long-term outcomes. a: Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modeling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. doi:10.1136/bmj-2024-080952. About Vitalgen Vitalgen was founded in March 2020 as a cell and gene therapy (CGT) company based in Shanghai, China, dedicated to translating cutting-edge CGT technologies into clinically accessible treatments for patients worldwide. With proprietary intellectual property rights covering three core CGT platforms: ViVec® (AAV manufacturing platform), ViCas® (CRISPR gene-editing platform) and ViLNP® (Lipid nanoparticle delivery platform), Vitalgen has developed a diversified portfolio of innovative CGTs targeting CNS diseases, ophthalmic conditions, metabolic and hematologic disorders, and oncology, including multiple potential First-in-Class (FIC) products. Up-to-date, Vitalgen has received multiple rounds of investment from renowned venture funds and has established CGT R&D labs and operational centers in the Zhangjiang High-tech Park and a GMP commercial production facility in the Waigaoqiao Free Trade Zone, Shanghai, China. David Wu Vitalgen BioPharma email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
